Research Progress on Multi-Specific Antibodies against Newly Emerging
Infectious Diseases
Abstract
In recent years, the world has witnessed in the emergence of several
infectious diseases, with notable examples being coronavirus disease
2019 (COVID-19), avian influenza, and Mpox, which continue to present
serious and persistent threats to global public health. The rapid spread
and devastating impact of these diseases underscore the urgent need for
effective combat strategies. One promising area of research in the field
of antiviral drug development is the exploration of multi-specific
antibodies. These have attracted significant attention owing to their
diverse benefits compared to monoclonal antibodies. Multi-specific
antibodies exhibit a more versatile function, possess a stronger binding
affinity for viral targets, demonstrate enhanced antiviral activity, and
show reduced susceptibility to viral escape mechanisms. These
characteristics make them promising candidates for the development of
novel antiviral therapies against a range of emerging infectious
diseases. This review examines the current research progress surrounding
multi-specific antibodies in the context of combating SARS-CoV-2,
influenza virus, and other newly emerging infectious viruses. It offers
insights into the potential applications and future prospects of
multi-specific antibodies, with the aim to contribute to the ongoing
efforts to address the global health challenges posed by infectious
diseases.